NIA-AA guidelines follow the creed of the β-amyloid cascade hypothesis that assumes β-amyloid as the prime neuropathological change in AD and the requirement for its diagnosis; tau pathology is a consequence of the effects of Aβ [206, 207]. Here, MAPT is linked to Alzheimer disease.